Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Haohai Biological Technology Co has a Cash Ratio of 2.66. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
Shanghai Haohai Biological Technology Co (FRA:5HB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Shanghai Haohai Biological Technology Co Cash Ratio Related Terms
Shanghai Haohai Biological Technology Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co Cash Ratio Chart
Shanghai Haohai Biological Technology Co Annual Data
FRA:5HB vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co Cash Ratio vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co (FRA:5HB) has a Cash Ratio of 2.66 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Shanghai Haohai Biological Technology Co and its competitors. This is 31% below median its historical median of 3.84. Over the past decade, Shanghai Haohai Biological Technology Co's Cash Ratio has ranged from 2.50 to 11.69. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #720 out of 1318 companies in the Biotechnology industry, placing it in the top 54.6%.
Is Shanghai Haohai Biological Technology Co's Cash Ratio too high?
Shanghai Haohai Biological Technology Co's current Cash Ratio of 2.66 is 31% below median its 10-year median of 3.84. Over the past 10 years, this metric has ranged from a low of 2.50 to a high of 11.69. The Biotechnology industry median Cash Ratio is 3.02. Shanghai Haohai Biological Technology Co's value of 2.66 is 11.8% below this industry median. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #720 out of 1318 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #720 out of 1318 companies for Cash Ratio. This places Shanghai Haohai Biological Technology Co in the lower half of its industry. The industry median Cash Ratio is 3.02. Shanghai Haohai Biological Technology Co's value of 2.66 is 11.8% below this benchmark. Historically, Shanghai Haohai Biological Technology Co's own Cash Ratio has ranged from 2.50 to 11.69 over the past decade. While the company's 10-year median is 3.84 vs. the industry median of 3.02, Shanghai Haohai Biological Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 3.02, based on 1,318 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haohai Biological Technology Co's current Cash Ratio of 2.66 is 11.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Shanghai Haohai Biological Technology Co and its competitors. For the Biotechnology industry, the median Cash Ratio is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current Cash Ratio is 2.66, which is 31% below median its own 10-year median of 3.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Shanghai Haohai Biological Technology Co (FRA:5HB) has a current Cash Ratio of 2.66. The stock's GF Value™ is €2.78, compared to a current price of €1.76 — trading 36.7% below its estimated fair value. The current Cash Ratio is 2.66, which is 31% below median its 10-year median of 3.84 and 11.8% below the Biotechnology industry median of 3.02. Shanghai Haohai Biological Technology Co's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current Cash Ratio is 2.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.76 is trading 36.7% below its estimated GF Value™ of €2.78.
Key valuation signals for FRA:5HB:
Cash Ratio: 2.66 (31% below median its 10-year median of 3.84)
GF Value™: €2.78 vs. price of €1.76 (36.7% below fair value)
Industry Position: 11.8% below the Biotechnology median (#720 of 1318)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
86GF Score
Get the complete analysis for FRA:5HB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
